ArticleJournal of translational medicine2026
INHBA secreted by cancer-associated fibroblasts promotes cisplatin resistance and malignant progression of ovarian cancer via ENG-mediated suppression of apoptosis and induction of EMT.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPlatinum resistance remains a major cause of treatment failure in ovarian cancer (OC). Cancer-associated fibroblasts (CAFs), key components of the tumor microenvironment, play critical roles in OC progression. Inhibin subunit beta A (INHBA) and its putative receptor endoglin (ENG) have been linked to OC chemoresistance, but their functional interaction in mediating cisplatin resistance remains unclear.
methodsSingle-cell RNA sequencing (scRNA-seq) was performed to characterize CAF subsets and assess INHBA and ENG expression in OC tissues. Immunohistochemistry (IHC) and immunofluorescence (IF) staining was conducted on tissue microarrays to evaluate protein expression and co-localization. Primary CAFs and normal fibroblasts (NFs) were isolated. INHBA was knocked out in CAFs via CRISPR/Cas9, and ENG was stably knocked down in cisplatin-resistant OC cells by lentiviral shRNA. The INHBA-ENG axis was investigated through in vitro assays, co-immunoprecipitation (Co-IP), molecular docking, and in vivo xenograft models.
resultsscRNA-seq resolved four CAF subsets, with myoCAF1 being dominant in platinum-resistant tumors. INHBA was specifically restricted to myoCAF1, while ENG was enriched in epithelial cells, and their mRNA levels showed a strong positive correlation. Consistently, IHC confirmed significant upregulation of INHBA/ENG in OC, especially in platinum-resistant cases. CAF-derived INHBA promoted OC cell proliferation, invasion, EMT, and cisplatin resistance. Molecular docking suggested a high-affinity INHBA-ENG interaction, which was confirmed by Co-IP in OC-CAF co-cultures. ENG knockdown reversed cisplatin resistance, an effect abrogated by recombinant INHBA. In vivo, CAF-derived INHBA promoted tumor growth and cisplatin resistance in an ENG-dependent manner.
conclusionsMyoCAFs-derived INHBA binds to ENG on OC cells, inhibits apoptosis, induces EMT, and promotes cisplatin resistance. The INHBA-ENG axis represents a promising therapeutic target for overcoming platinum resistance in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.